title: Bisphosphonates cause osteonecrosis of the jaw-like disease in mice.
abstract: Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is a morbid bone disease linked to long-term bisphosphonate use. Despite its broad health impact, mechanistic study is lacking. In this study, we have established a mouse model of BONJ-like disease based on the equivalent clinical regimen in myeloma patients, a group associated with high risk of BONJ. We demonstrate that the murine BONJ-like disease recapitulates major clinical and radiographical manifestations of the human disease, including characteristic features of osseous sclerosis, sequestra, avascular, and radiopaque alveolar bone in the jaw that persists beyond a normal course of wound healing following tooth extraction. We find that long-term administration of bisphosphonates results in an increase in the size and number of osteoclasts and the formation of giant osteoclast-like cells within the alveolar bone. We show that the development of necrotic bone and impaired soft tissue healing in our mouse model is dependent on long-term use of high-dose bisphosphonates, immunosuppressive and chemotherapy drugs, as well as mechanical trauma. Most importantly, we demonstrate that bisphosphonate is the major cause of BONJ-like disease in mice, mediated in part by its ability to suppress osseous angiogenesis and bone remodeling. The availability of this novel mouse model of BONJ-like disease will help elucidate the pathophysiology of BONJ and ultimately develop novel approaches for prevention and treatment of human BONJ.
authors.affiliation: University of Maryland School of Medicine, 800 W. Baltimore Street, Baltimore, MD 21201, USA.
authors.forename: Yanming
authors.initials: Y
authors.lastname: Bi
authors.forename: Yamei
authors.initials: Y
authors.lastname: Gao
authors.forename: Driss
authors.initials: D
authors.lastname: Ehirchiou
authors.forename: Chunzhang
authors.initials: C
authors.lastname: Cao
authors.forename: Takashi
authors.initials: T
authors.lastname: Kikuiri
authors.forename: Anh
authors.initials: A
authors.lastname: Le
authors.forename: Songtao
authors.initials: S
authors.lastname: Shi
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000494:pharmacology; D016723:Bone Remodeling / Q000187:drug effects; D003907:Dexamethasone / Q000494:pharmacology; D004164:Diphosphonates / Q000009:adverse effects* / Q000494:pharmacology; D000077143:Docetaxel; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology; D007571:Jaw Diseases / Q000139:chemically induced* / Q000473:pathology; D008334:Mandible / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010011:Osteocytes / Q000187:drug effects / Q000378:metabolism; D010020:Osteonecrosis / Q000139:chemically induced* / Q000473:pathology; D043823:Taxoids / Q000494:pharmacology; D000077211:Zoledronic Acid
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D043823:Taxoids; D000077143:Docetaxel; D000077211:Zoledronic Acid; D003907:Dexamethasone
references.citation: Endocrinology. 2000 Dec;141(12):4793-6
references.pmid: 11108295
references.citation: Nat Clin Pract Oncol. 2007 Jan;4(1):42-55
references.pmid: 17183355
references.citation: J Bone Miner Res. 2007 Oct;22(10):1479-91
references.pmid: 17663640
references.citation: J Bone Miner Res. 1987 Dec;2(6):595-610
references.pmid: 3455637
references.citation: Biomaterials. 2005 Dec;26(34):6941-9
references.pmid: 16009417
references.citation: J Neurosci. 2007 May 30;27(22):5976-80
references.pmid: 17537968
references.citation: Nat Med. 2007 Oct;13(10):1219-27
references.pmid: 17828274
references.citation: J Oral Maxillofac Surg. 2007 Mar;65(3):369-76
references.pmid: 17307580
references.citation: Dent Clin North Am. 2008 Jan;52(1):111-28, ix
references.pmid: 18154867
references.citation: J Oral Maxillofac Surg. 2003 Sep;61(9):1104-7
references.pmid: 12966490
references.citation: N Engl J Med. 2009 Jan 1;360(1):53-62
references.pmid: 19118304
references.citation: J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7
references.pmid: 12966493
references.citation: N Engl J Med. 2005 Jun 16;352(24):2487-98
references.pmid: 15958804
references.citation: Int J Cancer. 2003 Mar 10;104(1):121-9
references.pmid: 12532428
references.citation: N Engl J Med. 2002 Feb 28;346(9):653-61
references.pmid: 11870242
references.citation: J Histochem Cytochem. 2002 Mar;50(3):333-40
references.pmid: 11850436
references.citation: J Oral Pathol Med. 2006 Mar;35(3):155-60
references.pmid: 16454811
references.citation: JAMA. 2006 Jun 28;295(24):2833-6
references.pmid: 16804139
references.citation: J Bone Miner Res. 1995 Oct;10(10):1478-87
references.pmid: 8686503
references.citation: Oral Oncol. 2009 Feb;45(2):164-72
references.pmid: 18715819
references.citation: J Biol Chem. 1999 Dec 3;274(49):34967-73
references.pmid: 10574973
references.citation: Drugs. 2005;65(17):2513-31
references.pmid: 16296875
references.citation: Calcif Tissue Int. 2008 Mar;82(3):191-201
references.pmid: 18259679
references.citation: Ann Intern Med. 2006 May 16;144(10):753-61
references.pmid: 16702591
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8580-7
references.pmid: 16314620
references.citation: N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102
references.pmid: 16000365